Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Who May Qualify: - At least 18 years old and has provided willing to sign a consent form. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy. - tumors that can be measured on scans v1.1. - your organs (liver, kidneys, etc.) are working well enough based on blood tests (bone marrow, liver, kidney, coagulation). - One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy. - Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61). - Able to take oral medications. Who Should NOT Join This Trial: - Prior therapy with direct RAS-targeted therapy or docetaxel. - Untreated central nervous system (CNS) metastases. - Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function). - Ongoing anticancer therapy. - Pregnant or breastfeeding. Always talk to your doctor about whether this trial is right for you.